
AKAO
Other · Other
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · +16.1% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2018 | Time not confirmed | -1.00 | -0.92 | +8.0% |
| Aug 6, 2018 | Time not confirmed | -0.92 | -1.11 | -20.7% |
| May 4, 2018 | Time not confirmed | -0.89 | -1.06 | -19.1% |
| Feb 27, 2018 | Time not confirmed | -0.80 | -0.86 | -7.5% |
Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of…